Bausch + Lomb shares are down about 3% as the market revisits two connected negatives: the company’s enVista intraocular lens recall overhang and fresh waves of investor-attorney “investigation” headlines that keep litigation risk in focus. The combination is pressuring near-term sentiment even without a single company-filed update today, as traders price in uncertainty around surgical segment momentum and potential costs.

Bausch + Lomb previously disclosed that the voluntary recall of certain enVista IOLs created headwinds and impacted results, including an estimated revenue impact during 2025. Investors remain sensitive to any sign that the recall’s effects could linger into 2026 through slower procedure demand recovery, cautious surgeon adoption, or incremental quality/remediation expenses, all of which can compress margins and delay the company’s surgical growth trajectory. (ir.bausch.com)

A recent investor-focused announcement stated that an investigation was initiated into possible securities fraud and potential class-action claims, which can amplify volatility by increasing perceived headline risk and uncertainty around disclosures and damages exposure. Even when these notices don’t change fundamentals immediately, they can weigh on multiples and encourage short-term de-risking, especially in a stock already associated with a high-profile product recall. (globenewswire.com)

Near-term, investors will watch for any concrete updates on enVista’s commercial ramp, surgical segment trends, and whether management commentary implies the recall overhang is fading or persisting. Separately, traders will monitor for any escalation from “investigation” notices to filed complaints, plus any incremental company disclosures that could clarify the magnitude and duration of financial impact.